Amgen Inc. (AMGN) Monthly Stock Update
Publication Date: September 22, 2024
Company Overview
Amgen Inc. (AMGN), founded in 1980 and based in Thousand Oaks, California, is a leading biotechnology company in the healthcare sector. Renowned for its commitment to innovation, Amgen specializes in the discovery, development, manufacturing, and delivery of human therapeutics. Its impressive product lineup includes well-known medications like Enbrel for autoimmune diseases, Prolia for osteoporosis, and Repatha for reducing cardiovascular risk. By catering to healthcare providers such as hospitals and pharmacies, Amgen has cemented its strong foothold in the pharmaceutical market, underscored by strategic partnerships with other major firms.
Financial Performance and Analyst Recommendations
With total revenues nearing $30.93 billion, Amgen demonstrates formidable financial health. Analysts are bullish on the stock’s performance, with a target high price projected at $381.00, indicating a potential upside of approximately 12.9% from the current stock price of $337.38. The average target price is positioned at $329.14, which reflects a generally optimistic outlook amid some acknowledgment of market risks. Notably, the median target price stands at $344.00, lending further credence to the investment recommendation of “buy” provided by market experts.
In terms of stock performance, AMGN’s twenty-three analysts have provided a favorable consensus with a mean recommendation of 2.4, suggesting substantial investor confidence. The current short interest is low, with only 1.58% of shares held short, indicating a lack of bearish sentiment toward the company, which could bolster price stability in the coming months.
Stock Performance and Market Trends
Amgen’s current stock price of $337.38 lies comfortably between its fifty-day moving average of $329.51 and its fifty-two week high of $346.85, showcasing relatively strong market performance. Over the past year, the stock has rebounded significantly from a fifty-two week low of $249.70, recovering more than $87, pointing to positive momentum in its trajectory. As the stock approaches its recent peak, investors should watch for possible resistance levels, as overcoming these could provide greater bullish sentiment and drive further gains.
In summary, Amgen Inc. remains a formidable player in the biotech space with a robust financial foundation and favorable market outlook, making it a compelling option for investors seeking exposure to the pharmaceutical sector.
Metric | Value |
---|---|
Market Cap | $181.3b |
Total Debt | $62.6b |
Total Cash | $9.3b |
Shares Outstanding | 537.3m |
Float Shares | 535.8m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.